Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555819 | 0.93 | HTR6 (0.54) | HTR6AVPR1BOXTR | |
| SCHEMBL3558220 | 0.93 | HTR6 (0.43) | HTR6L3MBTL1AVPR1BOXTRPSEN1 | |
| SCHEMBL3557970 | 0.91 | HTR6 (0.46) | HTR6L3MBTL1AVPR1B | |
| SCHEMBL3555613 | 0.89 | HTR6 (0.48) | HTR6AVPR1BOXTR | |
| SCHEMBL3556781 | 0.88 | HTR6 (0.44) | HTR6 | |
| SCHEMBL3565168 | 0.87 | HTR6 (0.52) | HTR6AVPR1BOXTR | |
| SCHEMBL3558722 | 0.86 | HTR6 (0.39) | HTR6PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3559230 | 0.84 | HTR6 (0.38) | HTR6PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3564035 | 0.84 | HTR6 (0.58) | HTR6 | |
| SCHEMBL3560474 | 0.83 | HTR6 (0.52) | HTR6AVPR1BOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | claimed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | claimed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | claimed |
| EP-1567492-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | Suven Life Sciences Limited (IN) | 2005-08-31 | — | — | EP | claimed |
| WO-2004048328-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | claimed |
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | disclosed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | HTR6 56/4885L3MBTL1 3496/4885AVPR1B 955/4885 |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | HTR6 56/4885L3MBTL1 3496/4885AVPR1B 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.